Ian Jones, MRCPsych, PhD, Vice-Chair, Section of Perinatal Psychiatry, Royal College of Psychiatrists, and National Centre for Mental Health, Cardiff University; Liz McDonald, MRCPsych, Chair, Section of Perinatal Psychiatry, Royal College of Psychiatrists, and East London NHS Foundation Trust, UK.
Br J Psychiatry. 2014 Aug;205(2):103-4. doi: 10.1192/bjp.bp.113.141713. Epub 2014 Aug 1.
There have been a large number of studies in recent years reporting on the reproductive safety of antidepressant medication. Some studies, but not all, have reported an association of antidepressant exposure in pregnancy and the subsequent development of autism spectrum disorders. It remains difficult to know whether the modest increase in risk is due to the medication, to the mood disorder itself, or to other confounding factors. For any individual woman the decision to commence or continue antidepressant medication in pregnancy must be made after a full consideration of the potential risks and benefits of all options, including non-pharmacological treatments. In making these difficult decisions it is important to recognise that episodes of severe psychiatric illness may have very serious negative consequences for the woman, her baby and her family, and these must be weighed against what is known about the risks of taking medication.
近年来,有大量研究报告了抗抑郁药物的生殖安全性。一些研究(但不是全部)报告了抗抑郁药物暴露与妊娠后自闭症谱系障碍的发展之间存在关联。目前仍难以确定这种适度的风险增加是由于药物本身、情绪障碍本身还是其他混杂因素所致。对于任何个体女性而言,在决定是否在怀孕期间开始或继续使用抗抑郁药物时,必须充分考虑所有选择(包括非药物治疗)的潜在风险和益处。在做出这些艰难的决定时,重要的是要认识到严重的精神疾病发作可能会对女性、她的婴儿和她的家庭产生非常严重的负面影响,而这些负面影响必须与已知的药物治疗风险相权衡。